LinkedIn Profile

Access Neurodyn historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:neurodyn 3277236 May 30th, 2019 12:00AM Neurodyn Inc. 136 3.00 Open Biotechnology May 30th, 2019 01:45PM May 30th, 2019 01:45PM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Open Neurprotection, Neuropathic pain, ALS, Animal Models, Parkinson's disease Open NRC-INH 550 University Avenue Charlottetown Prince Edward Island CA C1A4P3 Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Mar 19th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Mar 19th, 2018 07:37AM Mar 19th, 2018 07:37AM Open Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 17th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 16th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 15th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 14th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 13th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 12th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 11th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology
private:neurodyn 3277236 Feb 10th, 2018 12:00AM Neurodyn Inc. 113 4.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation. Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease. Neurodyn Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.